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The development of a radiation-induced sarcoma (RIS) in the post mastectomy thoracic treatment volume is an infrequent,
but recognized, event. Its frequency is rising in relation with increasing survival of breast cancer patients treated with adjuvant
radiation therapy, and is associated with poor prognosis despite treatment. We present a case of leiomyosarcoma in a patient
who underwent mastectomy followed by radiotherapy for invasive ductal carcinoma. A delayed TRAM ﬂap reconstruction was
performed 10 years after and a rapid growing mass under the reconstructed ﬂap appeared, on routine follow-up, twenty years
later. This report analyzes the diagnostic and therapeutic approach of patients with RIS.
Copyright © 2008 M. Olcina et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
The increasing survival rate in breast cancer patients makes
meticulous long-term follow up of secondary adverse eﬀects
of the used therapies necessary. Adjuvant radiotherapy to the
breast plays a signiﬁcant role in preventing local failure after
mastectomy in advanced disease [1]. The development of
secondary neoplasm is of particular importance, especially
sarcomas in women previously treated with radiation ther-
apy [2]. Case reports [3, 4] and the publications of large
series of important oncology centers [5]o rr e g i s t e r s[ 6]i s
a consequence of the increasing frequency of this type of
secondary neoplasms.
Leiomyosarcoma is the more prevalent sarcoma cat-
egory occurring after breast cancer in the Surveillance,
Epidemiology and End Result (SEER) data [5], although
most published reports describe angiosarcoma as the most
frequent histological entity following breast conservation
and radiation therapy [3].
Surgical approach is the usual management of these
neoplasms, but it is not alwayspossible because of tumor size
and localization. After revision of international databases,
the authors have not found any case report about a RIS
developing subsequent to delayed TRAM ﬂap breast recon-
struction.
2. CASE REPORT
We present a 57-year-old women diagnosed in 1986 of a
multicentric invasive ductal carcinoma of the right breast.
Histological examination of modiﬁed radical mastectomy,
done as the initial treatment, showed a notable axillary
extension with nineteen of twenty-ﬁve lymph nodes positive
for cancer and extracapsular rupture. Standard extension
exams were negative for metastases. She received postop-
erative chemotherapy consisting of 5 cycles of adriamycin
plus cyclophosphamide. Afterwards, radiation therapy was
delivered on right thoracic wall, internal mammary nodes,
supraclavicular fossa, and axilla at a total dose of 50Gy and a
10Gy boost on mastectomy scar.
Elevenyears after, delayed reconstructionwascarried out
usingadouble-pediculatedTRAMﬂap,withagoodcosmesis
and contralateral symmetric result.
Seven years after reconstruction and twenty years after
primary treatment,thepatient noticed aprogressivegrowing







Figure 1: (a) MRI: tumor growth on right breast area. (b) MRI:
myocutaneous ﬂap inﬁltration.
appearance of a bad limited, itching, and hard area on the
reconstructedbreast.Physicalexamshowedatumorofabout
15 centimetres, ﬁxed to the thoracic wall and suggestive of
tumor failure.
Magnetic resonance imaging revealed a tumor (13×16×
10 centimetres) located on the right breast area, inﬁltrating
to a large extent the myocutaneous ﬂap and the adjacent
costal wall, mostly on the inferior border (Figures 1(a)
and 1(b)). The biopsy demonstrated a tumor composed of
fascicles of elongated spindle-shaped cells with eosinophilic
cytoplasm and blunt-ended (cigar-shaped) nuclei. Some
pleomorphic, multilobulated malignant cells were reported.
Immunohistochemical staining showed similar cellular fea-
tures and the presence of smooth muscle actin in the
cytoplasm (Figures 2(a) and 2(b)).
Primary systemic treatment was suggested because of
large thoracic extension of the sarcoma, in the intention
of reducing tumor size and limiting the neoplasm, making
it aﬀordable to surgical treatment. The patient received




Figure 2: (a) HE staining: fascicles of elongated spindle-shaped
cells. (b) Immunohistochemical staining: presence of smooth




Radiation-induced leiomyosarcoma of the breast seems to
becomeincreasinglycommon,withpatientsbeingdiagnosed
years after the radiation therapy, as survival of these women
is enhanced because of multimodal treatment. The cumula-
tive RIS incidence is 0.07% (±0.02) at 5 years, 0.27% (±0.05)
at 10 years, and 0.48% (±0.11) at 15 years. The standardized
incidence ratio (SIR) is 10.2 (95% CI, 9.03–11.59) for the
irradiated population compared with the general population
and 1.3 (95% CI, 0.3–3.6) for patients with breast carci-
noma who did not receive radiotherapy with the general
population’s risk, as the data of the largest published paper
[5]. These results are similar to those published by Taghian
et al. in their study about eleven radiation induced sarcomas
in 6919 irradiated patients [7]. The Instituto Valenciano de
Oncolog´ ıa has previously reported a RIS in a woman after
breast conserving therapy [4].
RIS diagnosis is done using the criteria established by
Cahan et al.: (1) record of radiation therapy, (2) asymp-
tomatic latency period of several years, (3) occurrence
of sarcoma within a previously irradiated ﬁeld, and (4)
histologic conﬁrmation of the sarcomatous nature of the
neoplasm [8, 9].
Clinical features include patients with a complete remis-
sion of the primary tumors, the latency period ﬂuctuating
between3and20.3yearsbeforethesecondarysarcomagrowsM. Olcina et al. 3
[10]. The patient described in this report was tumor free
twenty years after primary treatment. A tumor developing in
the irradiated volume years after radiation treatment should
raise suspicion about a radiation-induced sarcoma. Wide
excisionandpathologicalexamarerecommendedtoconﬁrm
the suspicion [11]. We have performed a percutaneous
biopsy, because the large tumor extension and costal wall
inﬁltration made primary surgical excision impossible.
In the experience of SEER of 274.572 breast cancer
patients diagnosed between 1973 and 1996, the most
prevalent sarcoma category occurring after breast cancer
was leiomyosarcoma (22.1%), followed by malignant ﬁbrous
histiocytoma (15.2%), angiosarcoma (13.7%), and liposar-
coma (8.7%) [6]. The Institut Curie clinical practice about
16705 breast cancer patients shows angiosarcoma as the
most frequent histologic subtype (48%) [10]. Diﬀerent
staining with immunohistochemical procedures permits a
correct histological diﬀerentiation. Biopsy staining with
immunoperoxidase shows the presence of vimentin and
smooth muscle actin in the cytoplasm of leiomyosarcoma
[12].
Usual therapeutic management includes wide surgical
resection to obtain broad tumor free margins. RIS is often
located in anatomic areas that preclude radical surgery,
and diagnoses in advanced disease rules out surgical man-
agement, as happened in our patient. In our case, exten-
sive costal wall extension excluded surgery and primary
chemotherapy was intended with the aim of reducing tumor
burden and allowed radical excision. As tumor progression
developed after chemotherapy, surgery was discarded.
Experience described with systemic treatment has
been disappointing, obtaining a small number of clini-
cal responses. Kuten published, in 1985, the results of
seven patients with RIS after irradiation for breast cancer,
treated with standard four-drug combination. All 7 patients
died within six to 36 months after RIS diagnosis [13].
Most authors did not found any evidence of beneﬁt after
chemotherapy in RIS patients [3].
This case report points out the need for a careful follow-
up for breast cancer patients, because of the possibility of
secondary tumors, not only local failures or contralateral
tumors, but also treatment related. If an RIS is suspected,
the correct way for quick diagnoses includes a CT scan and
a magnetic resonance imaging, in association with a core
biopsy and detailed immunohistochemical analysis. Surgical
treatment, if possible, oﬀers the best treatment option.
REFERENCES
[1] L. E. Rutqvist, B. Cedermark, U. Glas, et al., “Radiotherapy,
chemotherapy, and tamoxifen as adjuncts to surgery in
early breast cancer: a summary of three randomized trials,”
International Journal of Radiation Oncology Biology Physics,
vol. 16, no. 3, pp. 629–639, 1989.
[2] A. I. Neugut, M. D. Weinberg, H. Ahsan, and J. Rescigno,
“Carcinogenic eﬀects of radiotherapy for breast cancer,”
Oncology, vol. 13, no. 9, pp. 1245–1256, 1999.
[3] M. M. Hanasono, M. P. Osborne, E. J. Dielubanza, S. B.
Peters, and L. B. Gayle, “Radiation-induced angiosarcoma
after mastectomy and TRAM ﬂap breast reconstruction,”
Annals of Plastic Surgery, vol. 54, no. 2, pp. 211–214, 2005.
[4] A. Garc´ ıa-Vilanova, C. V´ azquez-Albaladejo, S. Almenar-
Medina, et al., “Angiosarcoma mamario tras tratamiento
conservador del c´ ancer de mama. A prop´ osito de un caso,”
Revista de Senolog´ ıa y Patolog´ ıa Mamaria,v o l .7 ,n o .3 ,p p .
141–146, 1994.
[5] Y. M. Kirova, J. R. Vilcoq, B. Asselain, X. Sastre-Garau, and
A. Fourquet, “Radiation-induced sarcomas after radiotherapy
for breast carcinoma: a large-scale single-institution review,”
Cancer, vol. 104, no. 4, pp. 856–863, 2005.
[ 6 ]J .Y a p ,P .J .C h u b a ,R .T h o m a s ,e ta l . ,“ S a r c o m aa sas e c o n d
malignancy after treatment for breast cancer,” International
Journal of Radiation Oncology Biology Physics, vol. 52, no. 5,
pp. 1231–1237, 2002.
[7] A. Taghian, F. de Vathaire, P. Terrier, et al., “Long-term risk
of sarcoma following radiation treatment for breast cancer,”
International Journal of Radiation Oncology Biology Physics,
vol. 21, no. 2, pp. 361–367, 1991.
[8] W. G. Cahan, H. Q. Woodard, N. L. Higinbotham, F. W.
Stewart, and B. L. Coley, “Sarcoma in irradiated bone. Report
of eleven cases,” Cancer, vol. 1, no. 1, pp. 3–29, 1948.
[9] A. G. Huvos, H. Q. Woodard, W. G. Cahan, et al., “Postra-
diation osteogenic sarcoma of bone and soft tissues. A
clinicopathologic study of 66 patients,” Cancer, vol. 55, no. 6,
pp. 1244–1255, 1985.
[10] Y. Kirova, J. R. Vilcoq, B. S. Asselain, et al., “Sarcomes radio-
induits apr` es cancer du sein: exp´ erience de l’institute Curie et
r e v u ed el al i t t ´ erature,” Cancer Radiother, vol. 10, pp. 83–90,
2006.
[11] F.Plotti,V.DiDonato,M.A.Zullo,R.Angioli,andP.B.Panici,
“An unusual case of secondary ﬁbrosarcoma after treatment
for breast cancer,” Gynecologic Oncology, vol. 103, no. 3, pp.
1133–1136, 2006.
[12] D. Weedon, Skin Pathology, Churchill Livingstone, New York,
NY, USA, 2nd edition, 2002.
[ 1 3 ]A .K u t e n ,D .S a p i r ,Y .C o h e n ,N .H a i m ,R .B o r o v i k ,a n d
E. Robinson, “Postirradiation soft tissue sarcoma occuring
in breast cancer patients: report of seven cases and results
of combination chemotherapy,” Journal of Surgical Oncology,
vol. 28, no. 3, pp. 168–171, 1985.